Compare Abbott Laboratories (ABT) vs BHP Billiton Limited (BHP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs BHP Billiton Limited — how do they compare? Abbott Laboratories trades at $95.13 (market cap $166.94B), while BHP Billiton Limited trades at $78.3 (market cap $206.17B). The key difference: BHP Billiton Limited is the larger of the two by market cap, and BHP Billiton Limited pays the higher dividend (3.32%). Which is the better fit depends on your goals.
| ABT | BHP | |
|---|---|---|
Market Cap | $166.94B | $206.17B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $93.15 |
52-Week Low | $82.57 | $49.36 |
Enterprise Value | $193.69B | $220.38B |
Dividend Yield | 2.63% | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
BHP trades at $80.23, down 3.72% over the past 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2025 EPS of $2.12, beating expectations, but missed in Q4 2025. Recent news includes a $2.3 billion writedown at the Jansen potash project and leadership changes under incoming CEO Brandon Craig. Financials show strong profitability with an 18.97% net income margin and $20.67B in operating cash flow for 2024.
BHP's outlook is supported by robust cash flows and strategic focus on copper, but faces risks from cost overruns and labor disputes. Analyst consensus is mixed with 22.58% buy ratings. The stock presents a value opportunity with a P/E of 20.77, though investors should monitor execution on growth projects and commodity price volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →
